Publications

We work hard to attract, retain, and support the most outstanding faculty.

Filter by

TO REMOVE

Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante : résultats à 3 ans d’une étude de phase IIb.

2021

Authors: D. Van Der Heijde, A. Deodhar, L. Gensler, D. Poddubnyy, A. Kivitz, M. Dougados, N. De Peyrecave, M. Oortgiesen, T. Vaux, C. Fleurinck, X. Baraliakos

TO REMOVE

Poursuite ou arrêt du traitement par l’ixékizumab chez des patients atteints de spondyloarthrite axiale et ayant atteint la rémission : résultats d’une étude de retrait randomisé, contrôlée versus placebo.

2021

Authors: R. Landewé, L. Gensler, D. Poddubnyy, P. Rahman, M. Hojnik, X. Li, S. Liu-Leage, D. Adams, H. Carlier, F. Van den Bosch, C. Lukas

TO REMOVE

The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort.

2021

Authors: Liew JW, Jafarzadeh SR, Dubreuil M, Heckbert SR, Mooney SJ, Brown MA, Ishimori ML, Reveille JD, Ward MM, Weisman MH, Gensler LS

Journal of geriatric oncology

SIOG2021-0067* “You have to be sure that the patient has the full picture”: Adaptation of the Best Case/Worst Case (BC/WC) communication tool to geriatric oncology.

2021

Authors: M. Wong, F. Nicosia, A. Smith, L. Walter, V. Lam, H. Cohen, K.P. Loh, S. Mohile, C. Ursem, M. Schwarze

TO REMOVE

The visual abstract: A social media fad or the future of dissemination.

2021

Authors: Castellanos A, Wray CM

TO REMOVE

Simulation-Based Training in Medical Education: Immediate Growth or Cautious Optimism?

2021

Authors: Brooks M, Wray CM

TO REMOVE

A Preclinical Medical School Curriculum on Firearm Violence to Develop Patient Counseling and Foundational Health Policy Skills.

2021

Authors: Kucirek N, Studenmund C, Cordero DM, Garg M

Medical education online

Evaluation of a longitudinal subspecialty clinic for internal medicine residents.

2021

Authors: Consunji MV, Kohlwes RJ, Babik JM

Medical education online

A single center evaluation of applicant experiences in virtual interviews across eight internal medicine subspecialty fellowship programs.

2021

Authors: Huppert LA, Hsu G, Elnachef N, Flint L, Frank JA, Gensler LS, Hsiao EC, Khanna RR, Qasim A, Schwartz BS, Widera E, Zapata C, Babik JM

JAMA network open | Volume 4 of Issue 12

Sociodemographic Characteristics, Comorbidities, and Mortality Among Persons Diagnosed With Tuberculosis and COVID-19 in Close Succession in California, 2020.

2021

Authors: Nabity SA, Han E, Lowenthal P, Henry H, Okoye N, Chakrabarty M, Chitnis AS, Kadakia A, Villarino E, Low J, Higashi J, Barry PM, Jain S, Flood J

View Abstract

IMPORTANCE

Tuberculosis (TB) and COVID-19 are respiratory diseases that disproportionately occur among medically underserved populations; little is known about their epidemiologic intersection.

OBJECTIVE

To characterize persons diagnosed with TB and COVID-19 in California.

DESIGN, SETTING, AND PARTICIPANTS

This cross-sectional analysis of population-based public health surveillance data assessed the sociodemographic, clinical, and epidemiologic characteristics of California residents who were diagnosed with TB (including cases diagnosed and reported between September 3, 2019, and December 31, 2020) and COVID-19 (including confirmed cases based on positive results on polymerase chain reaction tests and probable cases based on positive results on antigen assays reported through February 2, 2021) in close succession compared with those who were diagnosed with TB before the COVID-19 pandemic (between January 1, 2017, and December 31, 2019) or diagnosed with COVID-19 alone (through February 2, 2021). This analysis included 3 402 713 California residents with COVID-19 alone, 6280 with TB before the pandemic, and 91 with confirmed or probable COVID-19 diagnosed within 120 days of a TB diagnosis (ie, TB/COVID-19).

EXPOSURES

Sociodemographic characteristics, medical risk factors, factors associated with TB severity, and health equity index.

MAIN OUTCOMES AND MEASURES

Frequency of reported successive TB and COVID-19 (TB/COVID-19) diagnoses within 120 days, frequency of deaths, and age-adjusted mortality rates.

RESULTS

Among the 91 persons with TB/COVID-19, the median age was 58.0 years (range, 3.0-95.0 years; IQR, 41.0-73.0 years); 52 persons (57.1%) were male; 81 (89.0%) were born outside the US; and 28 (30.8%) were Asian or Pacific Islander, 4 (4.4%) were Black, 55 (60.4%) were Hispanic or Latino, 4 (4.4%) were White. The frequency of reported COVID-19 among those who received a TB diagnosis between September 3, 2019, and December 31, 2020, was 225 of 2210 persons (10.2%), which was similar to that of the general population (3 402 804 of 39 538 223 persons [8.6%]). Compared with persons with TB before the pandemic, those with TB/COVID-19 were more likely to be Hispanic or Latino (2285 of 6279 persons [36.4%; 95% CI, 35.2%-37.6%] vs 55 of 91 persons [60.4%; 95% CI, 49.6%-70.5%], respectively; P < .001), reside in low health equity census tracts (1984 of 6027 persons [32.9%; 95% CI, 31.7%-34.1%] vs 40 of 89 persons [44.9%; 95% CI, 34.4%-55.9%]; P = .003), live in the US longer before receiving a TB diagnosis (median, 19.7 years [IQR, 7.2-32.3 years] vs 23.1 years [IQR, 15.2-31.5 years]; P = .03), and have diabetes (1734 of 6280 persons [27.6%; 95% CI, 26.5%-28.7%] vs 42 of 91 persons [46.2%; 95% CI, 35.6%-56.9%]; P < .001). The frequency of deaths among those with TB/COVID-19 successively diagnosed within 30 days (8 of 34 persons [23.5%; 95% CI, 10.8%-41.2%]) was more than twice that of persons with TB before the pandemic (631 of 5545 persons [11.4%; 95% CI, 10.6%-12.2%]; P = .05) and 20 times that of persons with COVID-19 alone (42 171 of 3 402 713 persons [1.2%; 95% CI, 1.2%-1.3%]; P < .001). Persons with TB/COVID-19 who died were older (median, 81.0 years; IQR, 75.0-85.0 years) than those who survived (median, 54.0 years; IQR, 37.5-68.5 years; P < .001). The age-adjusted mortality rate remained higher among persons with TB/COVID-19 (74.2 deaths per 1000 persons; 95% CI, 26.2-122.1 deaths per 1000 persons) compared with either disease alone (TB before the pandemic: 56.3 deaths per 1000 persons [95% CI, 51.2-61.4 deaths per 1000 persons]; COVID-19 only: 17.1 deaths per 1000 persons [95% CI, 16.9-17.2 deaths per 1000 persons]).

CONCLUSIONS AND RELEVANCE

In this cross-sectional analysis, TB/COVID-19 was disproportionately diagnosed among California residents who were Hispanic or Latino, had diabetes, or were living in low health equity census tracts. These results suggest that tuberculosis and COVID-19 occurring together may be associated with increases in mortality compared with either disease alone, especially among older adults. Addressing health inequities and integrating prevention efforts could avert the occurrence of concurrent COVID-19 and TB and potentially reduce deaths.

View on PubMed